Andogsky Syndrome: Experience with Anti-IL-4,13 Therapy

Andogsky syndrome with signs of T2 inflammation and ectodermal structure involvement is a complex disease characterized by a combination of atopic dermatitis and progressive juvenile cataracts. The high risks of disability in young patients, due to the danger of developing persistent visual impairments, require special attention to this patient group. Measures aimed at controlling inflammation, preventing ophthalmological complications, and timely surgical intervention, if necessary, require constant dynamic monitoring by an allergist-immunologist and an ophthalmologist. The therapeutic strategy for severe Andogsky syndrome involves a comprehensive interdisciplinary approach with the rational use of modern systemic therapy. Dupilumab, a monoclonal antibody targeting the alpha subunit of the interleukin (IL)-4 and IL-13 receptor, has dramatically changed the treatment approach for atopic conditions such as atopic dermatitis (AD), bronchial asthma, and chronic rhinosinusitis. However, its expanding use has drawn increased attention to several undesirable ocular adverse events — conjunctivitis, blepharitis, keratitis, corneal ulcers, and cicatricial conjunctivitis — which remain underrecognized and often underestimated in clinical practice. These manifestations frequently occur in patients with atopic dermatitis and vary in severity, creating diagnostic and therapeutic challenges. The therapeutic potential of Dupilumab in treating Andogsky syndrome is of particular interest, given the complex nature of the disease and the involvement of various body systems. Suppression of T2 inflammation through inhibition of IL-4 and IL-13 leads to: reduction in the severity of skin manifestations, decrease in inflammatory process intensity, improvement in ophthalmological indicators. Further study of Dupilumab’s effectiveness in Andogsky syndrome will allow determining the optimal duration of therapy, assessing the impact on disease progression, developing personalized treatment approaches.